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The mevalonate (MVA) pathway plays an essential mle in cell 
proliferation. In fact, fmm MVA derive not only cholesterol (important for 
membrane assembly) but also two terpenes (famesol F-OH and 
geranylgeraniol GG-OH), utilized for post-translational modiiitions 
of cellular proteins, some of which are involved in cell duplication (ras, 
rho, rap). As we performed, before, several experiments in order to assess 
the antiproliferative properties of statins (competitive inhibitors of HMG- 
CoA reductase), we tested BZA-SB, a fmt generation benmdiazepine 
peptidomimeric (lo-50 PM) farnesyltransferase inhibitor (FIT) and three 
second generation Fl’Is, (SCH 56582 (l-30 PM) is a nonpeptidic non- 
sulphydril tricyclic FTI, while PD 152440 and PD 169451(1-50 PM) are 
peptidomimetic) onrat smooth muscle cell proliferation, evaluated both by 
cell count and 3H-thymidine incorporation i to nuclear DNA. All of them 
are able. even if at different concentrations, to dose-dependently decrease 
this process, without affecting cholesterol biosynthesis. Moreover, the 
second generation molecules eem 10 act in the middle-G1 phase of the 
cell-cycle (time-course experiments). Their inhibitory effect is not 
completely prevented by the addition of MVA, F-OH and GG-OH, as in the 
presence of statins, but only in part (BZA-5B) or not at all (PD 152440, PD 
169451 and SCH 56582). suggesting probably different mechanisms of 
action of these molecules. To assess if their inhibitory effect on cell growth 
was related to the ability in interfering with protein prenylation, we 
evaluated BZA-SB, SCH 56582 and PD 152440 on ‘H-F-OH and ‘H-GG- 
OH incorporation into specific cellular prote.ins (41-72 KDa and 21-28 
KDa), known to be physiok@caUy prenylated. The obtained resulu 
saongly suggest he relevance of the MVA pathway in the control of cell 
growth, and thanks to the property of these molecules to directly influence 
cell proliferation, probably through a modulation of protein prenylation, 
they might become of particular interest, at least in vitro in atherogenesis 
and turnours. 
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A RABBIT MODEL OF ATHEROSCLEROSIS WHICH 
MIMICS HUMAN SOFT, LIPID-RICH, PLAQUES 
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Laucello”, G. Franceechini’, V. Lorusso” and CR. Sittori* 
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Many animal models have been generated over the years, to 
study the progression of neointimal proliferation and its 
pharmacological prevention. In these models, however, the 
mtimal thickening IS prima@ consisting of smooth muscle cells 
and so resembling to what observed during restenosis rather 
than atherosclerosis. In our stud carotid arteries of NZ white 
rabbits were injured by electr c current, 7 usin 
microcoagulator. After surgery, animals were ed a 1.5% B 
a bipolar 
cholesterol diet; at different tme points ranging from 3 days to 
three months rabbi were sacrificed and hystological analysis 
of carotlds were performed. Moreover, before sacrifice, at the 
latest time points (@O and 90 days) carotids were analyzed 
angiografically by intravascular ultrasound (IVUS) using a 3.5 
F catheter. Electrical injury destroyed all medial smooth muscle 
cells and denuded the injured segment of intact endotelium. 
After 15 days repopulation of the media was observed mostly 
by lipid rich macrophages and neointimal formation started. At 
longer time points macrophages in the media were 
progressively replaced by smooth muscle cells and 
macrophages densely packed with Ii id droplets predominated 
within the neointimal formation. ntravascular ultrasound P 
performed at 60 and 90 days after injury detected poorly echo- 
reflective intimal thickening resemblin to human atheromatous 
plaques characterized by a thin brous cap and heavily f 
Infiltrated foam celts, frequently unstable and prone to rupture. 
In conclusion, a rabbit model of atherosclerosis was generated 
in which the formation of a lipid rich plaque is observed, thus 
providing a useful animal model for pharmacological treatment 
aimed to stabilize or promote regression of vulnerable 
atherosclerotic plaques. 
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A NOVEL PATHWAY FOR FIBROBLASTS ACTIVATION AND IL4 
RELEASE: POSSIBLE IMPLICATIONS IN ATHEROMA FORMATION 
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Ferrsq Fenam 
The physiological role of ofpurinergic receptors (PR) of the PZY and PZX 
subtypes, activated by ATP, is still unknown, although their involvement 
in many cellular functions (proliferation, cytokine secretion, cell death) has 
been proposed. Little information is available about heir presence in human 
cells. Human fibroblasts (HF) share several feam with smooth muscle 
cells and are directly involved in chronic degenerative diseases such as 
atherosclerosis; moreover, they are exposed to ATP released by endothelium 
after a shear stress and by platelets during thrombus formation. We have 
investigated responses to extracelhdar nucleotides in HF, evaluating: a) 
immunoreactivity b  Western blot with a specific anti P2XT antiserum; b) 
stimulation of plasma membrane depolarization (PMDep) by benzoyl- 
benzoyl-ATP (BzATP); c) changes in plasma permeability by fluorescent 
tracers YO-PRO and lucifer yellow (Ly); d) activation of Ca* influx by 
intracellular t apping of Fur&?-Ah4 and e) IL6 release by immunoassay. HF 
eqxess an atypical P2X, receptor, since stimulation with ATP or BzATP 
caused a slow but relevant uptake of Ly and no sign&ant cytotoxici5 
(LDH release ~3%). BzATP also induced a striking increasein cytoplasmic 
microvesicle formation ot due to increased pinocytosis and fully reversible 
upon nucleotide removal. We labelled Bz-ATP-stimulated HF with a 
monoclonal antibody directed against a specific Golgi marker, observing an 
increased staining of the Golgi apparatus. Two known blockers of PZX 
receptors, oxoATP and PPADS, fully inhibited the morphological chauges 
and partially (by 50%) the ion fluxes. The residual rise in intracellular Ca” 
and membrane depolarization was dependent on activation of a PZY-type 
receptor. The pharmacological sequence for Ca” release was: CTP zATP 
>>BzATP =GTP =UTP =ATPyS (278 2240 >>160 =163 =170 =152 
uM). The pharmacological sequence forPMDep was BzATP >CTP >>ATP 
=ATPyS =2MeATP (100>52 >>ll =12 =12%). Moreover, ATP triggered 
a large release of the pr+&lammatory cytokine IL6 in cells pre-m with 
PMA. We suggest hat I-IF express a P2Y receptor and an atypical P2X- 
ATP-gated channel, involved in release of IL-6. This pathway could be au 
additional target for pharmacological intervention in atherosclerotic disease 
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RELATIONSHIP BETWEEN, CELL GROWTH, 
CHOLESTEROL ESTERlFlCATlON AND MDR 
P-GLYCOPROTEIN INHIBITORS. 
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Recently, multidrug resistance (MDR) P-glycoproteins have 
been involved in the cholesterol transport from plasma membrane to 
the ER for esterification. Previous studies from our laboratory have 
shown that the MDR inhibitors progesterone (PG) and 
dehydroepiandrosterone (DHEA), decrease in a dose-dependent 
manner both cholesterol esterification and cell growth in different 
tumor cell lines. We have suggested that MDRl by modulating 
intracellular cholesterol ester levels may influence the rate of cellular 
growth. To further investigate the mechanisms by which such effect 
is produced, we have studied cholesterol metabolism, cell growth 
and P-glycoprotein activity in mitogen-stimulated lymphocytes and 
during the growth of CEM, MOLT4 and L1210 cell lines in presence 
of PG (40kM), (DHEA 6OpM) and W-466 (2mM). The results have 
shown that the inhibition of P-glycoprotein activii by PG and DHEA 
was accompanied by reduced intracellular cholesterol esterification 
and cell growth in all cell lines, either after a short (3 hrs) or a 
prolonged incubation (48 hrs) with the drugs. In mitogen-stimulated 
lymphocytes the two hormones were able to exert an inhibitory 
effect on cholesterol esterification and cell growth, but not on P- 
glycoprotein activii. RU-486 inhibited P-glycoprotein activity without 
affecting cholesterol esterification and cell growth in both, cell lines 
and mitogen-stimulated lymphocytes. However, RU-486. besides its 
antagonistic activity on PG receptors, failed to prevent the cellular 
effects of PG. These data add more evidence for the possible 
involvement of cholesterol esterification in the modulation of rate of 
cell growth. They, moreover, suggest that in the regulation of 
intracellular cholesterol metabolism different mechanisms other than 
MDRl P-glycoprotein pumps may be involved 
